CLS not significantly affected by tariffs
Clinical Laserthermia Systems announces that the proposed U.S. tariffs are expected to have minimal impact on the company, despite the fact that its products are manufactured in the EU and shipped to the U.S. The company’s U.S. operations are fully managed by its subsidiary, CLS Americas Inc., which gives CLS control over the import process. Additionally, the company’s agreements with partners already include clear terms on how tariffs are to be handled.
Clinical Laserthermia Systems (CLS) is currently working to strengthen its market position in neurosurgery with the ClearPoint Prism Neuro Laser Therapy System for MRI-guided laser ablation. The system is marketed and sold in the U.S. through the company’s partner, ClearPoint Neuro.
How is CLS affected by U.S. tariffs?
With the US introducing new tariffs, questions have arisen about the potential impact on Swedish companies. On Tuesday, CLS addressed the situation, stating that the tariffs are not expected to significantly affect its operations. This resilience is attributed to its U.S.-based subsidiary, EU-centered production, and well-defined agreements that outline how tariffs are to be managed.
The company’s import and sales in the US are entirely managed by its wholly owned subsidiary, CLS Americas Inc. This structure gives CLS full control over its business in the U.S. and reduces the risk of external disruptions. The tariffs will only apply to CLS AB’s priced products exported to CLS Americas Inc.
Clear agreements on tariff management and EU-based supply chain
CLS has included specific clear terms in its agreements with partners that govern how any potential tariffs are to be handled between the companies. This creates stability and predictability – a clear structure is already in place defining who is responsible for the associated costs.
The company’s production and supply chain are based within the EU, which minimizes exposure to other regions that may be affected by the tariffs. By relying on EU-based production, CLS is not dependent on third-party countries that may be more severely impacted by U.S. trade measures.
CLS CEO Dan Mogren comments on the situation:
– Our structure is designed to be resilient. Thanks to our EU-based supply chain, U.S. operations run by our own subsidiary, and clear agreements with partners, we are well positioned to continue delivering on our growth plans.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
